UK markets closed
  • FTSE 100

    6,938.56
    +0.32 (+0.00%)
     
  • FTSE 250

    22,372.26
    +7.39 (+0.03%)
     
  • AIM

    1,265.62
    +1.93 (+0.15%)
     
  • GBP/EUR

    1.1472
    -0.0041 (-0.36%)
     
  • GBP/USD

    1.3860
    +0.0017 (+0.12%)
     
  • BTC-GBP

    35,824.05
    -3,736.15 (-9.44%)
     
  • CMC Crypto 200

    1,140.35
    +16.45 (+1.46%)
     
  • S&P 500

    4,182.98
    +48.00 (+1.16%)
     
  • DOW

    34,042.37
    +226.47 (+0.67%)
     
  • CRUDE OIL

    61.71
    +0.28 (+0.46%)
     
  • GOLD FUTURES

    1,777.10
    -4.90 (-0.27%)
     
  • NIKKEI 225

    29,020.63
    -167.54 (-0.57%)
     
  • HANG SENG

    29,078.75
    +323.41 (+1.12%)
     
  • DAX

    15,279.62
    -40.90 (-0.27%)
     
  • CAC 40

    6,257.94
    -9.34 (-0.15%)
     

SOTIO to Present Preclinical Results Describing SOT102 as Treatment of Solid Tumors at the American Association of Cancer Research Annual Meeting

Sotio
·2-min read

PRAGUE, Czech Republic, April 06, 2021 (GLOBE NEWSWIRE) -- SOTIO, a clinical stage immuno-oncology company owned by PPF Group, today announced the presentation of a virtual poster at the 2021 American Association of Cancer Research Annual Meeting. The presentation focuses on preclinical data describing SOT102 which is intended for the treatment of CLDN18.2-expressing solid tumors.

SOT102 (earlier SO-N102) is a CLDN18.2 targeting antibody-drug conjugate based on a novel proprietary, highly-specific monoclonal antibody conjugated to a potent cytotoxic drug molecule exhibiting strong anti-tumor activity. SOT102 was studied in models of various CLDN18.2-positive solid tumors, mainly of gastric and pancreatic origin.

Poster Presentation details:

Title: SOT102, a novel CLDN18.2-targeting antibody-drug conjugate with strong anti-tumor effect in various solid tumors expressing low target levels

Poster Number: 1204

Session: PO.ET01.05 - New Targets

Presenting Author: Lenka Kyrych Sadilkova, Ph.D.

Date/ Time: Saturday, April 10, 2021 from 8:30 AM - 11:59 PM EST

Conference Registration Link: https://myaacr.aacr.org/LiveEventsList?ac__id=a4j1I000000Yd1r

A copy of the presentation materials can be accessed on the SOTIO website once the presentation concludes.

Company contact:

Media contact:

Richard Kapsa

Kirsten Frazer, Ph.D.

Head of Communication

LifeSci Communications

T: (+420) 224 174 448

T: +1 646-863-0222

M: (+420) 603 280 971

kfrazer@lifescicomms.com

kapsa@sotio.com

About SOTIO

SOTIO is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a platform to streamline personalized active immune cell therapies, CAR T platform and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group. For more information, please visit the company’s website at www.sotio.com.

SOTIO is a registered trademark of SOTIO a.s. in selected countries.